AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01762982 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Empty Finn Chamber
Description: Empty Finn Chamber
Study NCT01966705 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy, exposure and response prevention (Internet, guided)
Description: This intervention entails different exercises aimed at exposure to health anxiety stimuli.~Participants are guided by a therapist. Treatment is delivered via the Internet.
Study NCT01966705 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy, exposure and response prevention (Internet, unguided)
Description: This intervention entails different exercises aimed at exposure to health anxiety stimuli.~Participants are not guided by a therapist. Treatment is delivered via the Internet.
Study NCT01966705 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy, exposure and response prevention (Book, unguided)
Description: This intervention entails different exercises aimed at exposure to health anxiety stimuli.~Participants are not guided by a therapist. Treatment is delivered in book form.
Study NCT00516399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: povidone-iodine 1.25% ophthalmic solution
Study NCT02633592 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MRI Defecography
Description: Patients and healthy volunteers are investigated in the supine and left lateral position in the MRI
Study NCT00321191 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: No nitrous oxide
Study NCT00321191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of N2O
Study NCT03442439 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition and Play Intervention
Description: Mothers and children in the Nutrition and Play group will play educational and nutrition-focused games.
Study NCT03442439 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Nurture Intervention
Description: The mother-child pair will be asked to talk and play with each other as they customarily do. If the child becomes restless and dysregulated the mother will be coached by the Nurture Specialist to bring the child back into a calm state though sustained physical contact; comfort touch, soothing words, and eye contact.
Study NCT03298217 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Measurement of the peak tidal inspiratory flow (PTIF)
Description: In patients with bronchiolitis sverity mWCAS / 3-5 :~Nasopharyngeal aspiration and comfortable placement of the infant upon admission; Clinical evaluation: respiratory rate, respiratory distress scores rating (Silverman and m-WCAS); If the patient is eligible: information and collection of parental consent; If signed parental consent obtained: progressive (on at least 10 min) withdrawal of HFNC support and maintenance if necessary of conventional oxygen therapy (maximum 1 L/min); Application of the spirometer for the recording of 20 consecutive spontaneous respiratory cycles for PTIF measurements; Respiratory support with HFNC; flow adapted to the need of the patients (equal to the measured PTIF).
Study NCT03261011 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AK-104
Description: Subjects will receive AK104 by intravenous administration.
Study NCT00365703 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Feeding tube insertion
Description: 1. Orogastric feeding tube~2. Nasogastric feeding tube
Study NCT00948155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Intervention Drug (Varenicline (Chantix) will be administered in standard dosing in pill format: 0.5 mg days 1-3; 0.5 mg bid daily days 4-7; 1.0 mg bid daily days 8-21.
Study NCT00516399 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: natamycin ophthalmic suspension, USP 5%
Study NCT04453488 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RUTI® vaccine
Description: Each dose of the RUTI® vaccine contains 25 µg of fragmented, purified and liposomed heat-inactivated Mycobacterium tuberculosis bacilli.
Study NCT04453488 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Physiological serum, 0.9% NaCl, will be used as a placebo
Study NCT03809910 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prototype PTB (Combined mode)
Description: Participants will brush their teeth with prototype PTB toothbrush and 1.3 g ± 0.1 g of fluoride toothpaste (containing 0.76% w/w sodium monofluorophosphate) for 2-timed minute in Gum Line mode and 1-timed minute in Interdental mode under supervision of study staff.
Study NCT03223623 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TMS
Description: Single pulse TMS, IPL-M1 Interaction, IPL-M1 Interaction, Inhibitory Theta Burst Protocol (cTBS)
Study NCT03223623 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: TMS
Description: Single pulse TMS, IPL-M1 Interaction, IPL-M1 Interaction, Inhibitory Theta Burst Protocol (cTBS)
Study NCT03223623 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MRI
Description: High-resolution MRI for anatomical reference; fMRI scan as per research fMRI protocol will be conducted under 3 conditions. 1. Rest 2. Voluntary activity 3. Motor imagery task.
Study NCT03223623 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: MRI
Description: High-resolution MRI for anatomical reference; fMRI scan as per research fMRI protocol will be conducted under 3 conditions. 1. Rest 2. Voluntary activity 3. Motor imagery task.
Study NCT03223623 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VASO Imaging
Description: The voluntary activity condition will involve 4 tasks: a. individual tapping of two fingers (index and little), b. individual tapping of four fingers (index, middle, ring, and little; no thumb) interspaced with rest periods, c. individual tapping of all five fingers (index, middle, ring, little, and thumb) interspaced with rest periods and d. Alternating grasping or retraction of a rubber ball interspaced with rest periods.
Study NCT03223623 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: VASO Imaging
Description: The voluntary activity condition will involve 4 tasks: a. individual tapping of two fingers (index and little), b. individual tapping of four fingers (index, middle, ring, and little; no thumb) interspaced with rest periods, c. individual tapping of all five fingers (index, middle, ring, little, and thumb) interspaced with rest periods and d. Alternating grasping or retraction of a rubber ball interspaced with rest periods.
Study NCT02913768 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Study NCT02913768 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Study NCT01765725 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient education program
Description: Patient education program, 8 meetings, every other week, 2,5 hours per meeting.
Study NCT03172156 — intervention group
Intervention type: GENETIC
Intervention: ctDNA detection
Description: To detect ctDNA in Patients With Stage I Non-small Cell Lung Cancer (NSCLC) Using Secondary Gene Sequencing (NGS)
Study NCT03559699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-348
Description: Part 1 (Dose Optimization Period): Participants began by receiving 5 mg orally, BID. Each participant's dose of AG-348 was sequentially increased to 20 mg BID followed by 50 mg BID depending on their response to AG-348 and their tolerance.~Part 2 (Fixed Dose Period): Optimized dose determined in Part 1.
Study NCT05055882 — intervention group
Intervention type: OTHER
Intervention: children and adult with Still's disease in Auvergne-Rhône-Alpes-Limousin hospital
Description: Comparison of Adult-Onset Still's disease phenotypes
Study NCT00684827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levalbuterol HFA MDI followed by Racemic albuterol HFA MDI
Description: 1. Subjects will receive both treatments: (a) levalbuterol HFA MDI; 45 micrograms (16 cumulative doses); followed by (b) racemic albuterol HFA MDI; 90 micrograms (16 cumulative doses)~2. Arm #A~3. Xopenex HFA MDI, Pirbuterol HFA MDI
Study NCT00684827 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Racemic Albuterol followed by levalbuterol HFA MDI
Description: 1. Subjects will receive both treatments: (a) racemic albuterol HFA MDI; 90 micrograms (16 cumulative doses) followed by (b) levalbuterol HFA MDI; 45 micrograms (16 cumulative doses)~2. Arm #B~3. Pirbuterol HFA MDI, Xopenex HFA MDI
Study NCT01833234 — intervention group
Intervention type: OTHER
Intervention: Interviews and questionnaires
Study NCT02792023 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Immunochemical fecal occult blood test
Description: Participants will be provided with a single immunochemical fecal occult blood test. Participants will introduce a small sample of feces inside and bring the test to the hospital
Study NCT02792023 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Colonoscopy
Description: A colonoscopy (procedure performed using a scope design to examine the large bowel) will be offered to the participants
Study NCT02515955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ 54175446 Matching Placebo
Description: Participants will receive placebo matching with JNJ 54175446 once daily orally.
Study NCT02792023 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Upper endoscopy
Description: An upper endoscopy (procedure performed using a scope to examine the upper digestive tract) will be offered to the participants
Study NCT01364740 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PMP-300E
Description: Data collected from Level 3 device
Study NCT01364740 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: In-lab PSG
Description: Data collected from Type I In-Lab Polysomnography
Study NCT00710463 — intervention group
Intervention type: DEVICE
Intervention: non invasive ventilation (Resmed VPAP III ST-A, Respironics Harmony)
Description: non invasive ventilation was performed with commercially available ventilators from the manufacturers Resmed and Respironics.
Study NCT02215343 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Wheat bran extract
Description: Patients will be provided with 15g of wheat bran extract (WBE) (Cargill R\&D Centre Europe).
Study NCT02215343 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish oil
Description: Patients will be provided with a fish oil supplement (capsules), containing 3-4g of N-3 fatty acids (Axellus A/S, Ishøj, Denmark).
Study NCT02247180 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive rehabilitation
Study NCT02247180 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: standardized cognitive training
Study NCT00599690 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Epi-LASK
Description: 10 eyes of 10 patients underwent epi-LASK, epithelial flaps were created with the Amadeus II, epi-LASIK-LASIK microkeratome (Ziemer ophthalmics systems AG, Switzerland). A Visx star 4 system (Visx, Santa Ana, CA, USA) was used to perform the laser ablation in all eyes
Study NCT03025178 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 4Fr central venous catheter insertion
Description: The central venous catheter is placed at left internal jugular vein in infant, and its tip is confirmed by transthoracic echocardiography.
Study NCT02515955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D Amphetamine
Description: Participants will receive 20 mg d-amphetamine (AMPH) 2 hours after administration of study drug (JNJ-54175446/placebo or minocycline/placebo) on Day 7 and Day 10.
Study NCT01998945 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure-based Cognitive Behavioral Therapy
Description: Eight 75-minute, in-home sessions delivered twice weekly for 4 weeks of exposure-based cognitive behavioral therapy, a time-limited treatment that focuses on confronting avoided memories and situations and identifying and managing distressing thoughts.
Study NCT01998945 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation Training
Description: Eight 75-minute, in-home sessions delivered twice weekly for 4 weeks of Relaxation Training, that focus on muscle relaxation and diaphragmatic breathing to address the physical symptoms of anxiety.
Study NCT03365557 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Airway peak pressure
Description: Air was injected into LMA cuff during expiration phase to make intracuff pressure achieve the level of airway peak pressure. If there's any leakage, increase 5 cmH2O every time till there's no air leakage from the mouth.
Study NCT04166084 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active ROM Exercises
Description: Active ROM exercises programme will include hip flexion-extention, hip abduction-adduction, hip internal-external rotation, knee flexion-extention and ankle dorsi-plantar flextion exercises.
Study NCT04166084 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active ROM Exercises
Description: Active ROM exercises programme will include hip flexion-extention, hip abduction-adduction, hip internal-external rotation, knee flexion-extention and ankle dorsi-plantar flextion exercises.
Study NCT04166084 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trunk Stabilization Exercises Training
Description: Trunk stabilization exercises training will be given under the supervision of a physiotherapist. This training exercises will include diphragmatic exrecises, posterior pelvic tilt exercises, abdominal streghtening exercises,
Study NCT00687297 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: vandetanib induction
Description: 100 mg daily by mouth
Study NCT00687297 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vandetanib induction
Description: 100 mg daily by mouth
Study NCT00687297 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Docetaxel
Description: (75mg/m2) IV (in the vein) on day 1 of a 21-day cycle for 4 cycles or until disease progression
Study NCT00687297 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: (75mg/m2) IV (in the vein) on day 1 of a 21-day cycle for 4 cycles or until disease progression
Study NCT00687297 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: IV (in the vein) to area under the curve (AUC) of 6 on day 1 of a 21 day cycle, for 4 cycles or until disease progression
Study NCT00687297 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: IV (in the vein) to area under the curve (AUC) of 6 on day 1 of a 21 day cycle, for 4 cycles or until disease progression
Study NCT00687297 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00687297 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vandetanib maintenance
Description: 300 mg daily by mouth
Study NCT03006393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: One infusion of Infliximab (Remicade) will be administered intravenously (IV) at 5 mg/kg body weight over a two hour period.
Study NCT03006393 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One infusion of placebo treatment will be administered intravenously (IV) over a two hour period.
Study NCT03587415 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: preptin and amylin level
Description: we will take both of group blood samples to compare them serum preptin and amylin
Study NCT01005030 — intervention group
Intervention type: OTHER
Intervention: Blood draw
Description: Blood draw, two tubes, used for isolation of cell-free blood plasma
Study NCT03610009 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 2D ultrasound
Description: The timing of final follicle maturation and oocyte retrieval based on follicle tracking with use of conventional two-dimensional (2D) ultrasound.
Study NCT03610009 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SonoAVC
Description: The timing of final follicle maturation and oocyte retrieval based on follicle tracking with use of SonoAVC.
Study NCT01841385 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates method
Description: Therapeutic intervention in the Pilates method has two regular weekly sessions for 12 weeks, totaling 24 sessions. For the protocol of Pilates exercises, exercises on soil and equipment, with gradual progression of the load.
Study NCT03345706 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Selective cerebral hypothermia
Description: Subjects will be transferred to ICU for the 12-hour selective cerebral hypothermia procedure. Cooling will be initiated and targeted to reach ipsilateral nasal temperature of 27±2°C for 12 hours, followed by controlled rewarming.
Study NCT03345706 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Regular hypothermia
Description: Subjects will be transferred to ICU for the 12-hour selective cerebral hypothermia procedure. Subjects will receive systemic hypothermia via ECMO at 33.5±0.5°C (33-34°C) for 48 hours at the same time.
Study NCT03293043 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NPV-EVLP
Description: Lungs deemed marginal based on standard lung donor criteria that meet study eligibility will be physiologically assessed during ex-vivo perfusion. NPV-EVLP of these lungs will be performed with the addition of numerous pre-determined additives. With respect to the decision of lung utilization post-EVLP, eligibility criteria listed in the Post-NPV-EVLP section of the trial will need to be met. Lungs will also be excluded if they are deemed unsuitable based on the clinical judgment of the lung transplant surgeon.
Study NCT04050514 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: H-MAD with a hinge system according to Herbst
Description: The randomized grouping into blocks at a ratio of 1: 1 takes place over sealed envelopes containing the allocation key for the respective MAD. The assignment is stratified according to gender because gender is a strong predictor of sleep disorders and also temporomandibular dysfunctions Integration of the MAD (start of treatment) The laboratory-made MAD (F-MAD / H-MAD) is integrated and checked for a comfortable fit. The patient is instructed to always wear the splint during sleep.~All patients receive an extended guide to jaw gymnastics with the instruction to do it in the morning after waking up and in the evening before falling asleep.~Four weeks after incorporation, the titration phase begins, the slow adjustment of mandibular advancement to optimize sleep medical parameters while minimizing unwanted side effects.~Control appointments take place after four weeks, six months, one year and two years after insertion of the MAD
Study NCT04050514 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: H-MAD with a hinge system according to Herbst
Description: The randomized grouping into blocks at a ratio of 1: 1 takes place over sealed envelopes containing the allocation key for the respective MAD. The assignment is stratified according to gender because gender is a strong predictor of sleep disorders and also temporomandibular dysfunctions Integration of the MAD (start of treatment) The laboratory-made MAD (F-MAD / H-MAD) is integrated and checked for a comfortable fit. The patient is instructed to always wear the splint during sleep.~All patients receive an extended guide to jaw gymnastics with the instruction to do it in the morning after waking up and in the evening before falling asleep.~Four weeks after incorporation, the titration phase begins, the slow adjustment of mandibular advancement to optimize sleep medical parameters while minimizing unwanted side effects.~Control appointments take place after four weeks, six months, one year and two years after insertion of the MAD
Study NCT00201825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1250 mg/m2/day in 2 oral daily divided doses of 625 mg/m2 on day 5 of every cycle and continued for 14 days.
Study NCT00201825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 36 mg/m2 IV weekly for 3 weeks every 4 weeks.
Study NCT03419741 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation Clinical Research System
Description: Transcranial Magnetic Stimulation Clinical Research System is a US FDA approved treatment system for depression. The treatment research system includes motor threshold TMS coil, active TMS coil and sham TMS coil.
Study NCT03419741 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Magnetic Stimulation Clinical Research System
Description: Transcranial Magnetic Stimulation Clinical Research System is a US FDA approved treatment system for depression. The treatment research system includes motor threshold TMS coil, active TMS coil and sham TMS coil.
Study NCT00916994 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SpaceGuard Balloon
Description: Positioning of the balloon into the subacromial space between the humerus head and the acromion
Study NCT04284033 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extended Wear Infusion Set
Description: For two of the 4 weeks, the Extended Wear insulin infusion set will be used
Study NCT03695185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ravagalimab 600 mg
Description: Ravagalimab 600 mg was administered intravenously (IV).
Study NCT03695185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ravagalimab 300 mg
Description: Ravagalimab 300 mg was administered subcutaneously (SC).
Study NCT04284033 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard Infusion Set
Description: For two of the 4 weeks, the standard insulin infusion set will be used